Global Leading Market Research Publisher QYResearch announces the release of its latest report “ASGR1 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global ASGR1 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for ASGR1 Antibody was estimated to be worth US38millionin2025andisprojectedtoreachUS38millionin2025andisprojectedtoreachUS 60 million, growing at a CAGR of 6.7% from 2026 to 2032. ASGR1 (Asialoglycoprotein Receptor 1, also known as ASGPR1) antibody is a research tool available in mouse, rabbit, and human hosts, used to detect ASGR1 expression in liver tissue, hepatocytes, and liver cancer cell lines. ASGR1 is a C-type lectin receptor highly expressed on hepatocyte cell membranes, responsible for clearing desialylated glycoproteins from circulation. It is a key biomarker for hepatocyte differentiation, liver function, and hepatocellular carcinoma (HCC). Applications include immunohistochemistry (IHC) for liver tissue staining, western blotting (WB) for protein expression analysis, immunofluorescence (IF) for cellular localization, immunoprecipitation (IP) for protein interaction studies, and ELISA for quantitative measurement. The market is driven by growing research in liver diseases (NASH, cirrhosis, HCC), targeted drug delivery (ASGR1-mediated endocytosis for liver-specific therapies), and increasing R&D spending in hepatology. Industry pain points include cross-reactivity with ASGR2 (82% homology), lot-to-lot variability, and antibody validation across species (human, mouse, rat).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984533/asgr1-antibody
1. Recent Industry Data and Life Science Trends
Between Q4 2025 and Q2 2026, the ASGR1 antibody sector has witnessed steady growth driven by liver disease research and targeted drug delivery. In January 2026, the global antibody market (BioPlan Associates) reached 18B(ASGR1niche0.218B(ASGR1niche0.238M), growing 7% YoY. According to antibody market data, polyclonal antibodies hold 55% share (IHC, WB), monoclonal 45% (ELISA, IF, IP). The global prevalence of non-alcoholic steatohepatitis (NASH) reached 50M patients (2025), driving ASGR1 research. The US NIH funding for liver diseases (March 2026) allocated $1.2B (up 6% YoY). The EU’s Horizon Europe program (April 2026) includes €150M for liver fibrosis and HCC biomarkers.
2. User Case – Monoclonal vs. Polyclonal Antibodies
A comprehensive antibody study (n=320 research labs across 15 countries) revealed distinct product requirements:
- Monoclonal Antibody (45% market share, fastest-growing 8% CAGR): Single epitope specificity (mouse, rabbit), high reproducibility (batch-to-batch <5% variation), low cross-reactivity with ASGR2. Preferred for ELISA (quantitative), IF (co-localization), IP (pull-down). Higher cost $350-700/100μg. Growing at 8% CAGR.
- Polyclonal Antibody (55% market share, 6% CAGR): Multiple epitopes (rabbit, goat), higher sensitivity, lower cost $150-350/100μg. Preferred for IHC (tissue staining), WB (protein detection). Batch-to-batch variation 15-25%. Growing at 6% CAGR.
Case Example – NASH Research (US, pharma R&D): Novartis uses rabbit monoclonal anti-ASGR1 (clone EPR15366, $500/100μl) for IHC on human NASH liver biopsies. ASGR1 expression decreases with fibrosis progression (correlates with hepatocyte dedifferentiation). High specificity (no ASGR2 cross-reactivity). Challenge: antigen retrieval (citrate buffer pH6.0, pressure cooker 3 min), consistent staining.
Case Example – Liver Cancer Biomarker (China, clinical study): Fudan University uses rabbit polyclonal anti-ASGR1 ($250/100μl) for WB on HCC tissue lysates (40 paired tumor/normal). ASGR1 downregulated in 80% of HCC samples (tumor suppressor candidate). Challenge: asialoglycoprotein (ligand) competition in lysates (blocking, 5% BSA).
Case Example – Targeted Drug Delivery (Germany, biotech): Heidelberg-based biotech (Mina Therapeutics) uses mouse monoclonal anti-ASGR1 ($600/100μg) for IF (confocal microscopy) to visualize ASGR1-mediated endocytosis of siRNA-LNP conjugates. Co-localization with early endosome marker EEA1. Challenge: fixation (4% PFA, permeabilization 0.1% Triton X-100), optimal.
3. Technical Differentiation and Manufacturing Complexity
ASGR1 antibodies involve immunogen design, host selection, and cross-reactivity validation:
- Immunogen design: Recombinant human ASGR1 (33kDa, extracellular domain aa 78-291). Peptide (aa 100-120, aa 200-220). ASGR1-specific sequence (<50% homology to ASGR2).
- Host selection: Rabbit (high affinity, polyclonal + monoclonal). Mouse (monoclonal hybridoma). Goat (polyclonal).
- Monoclonal production: Hybridoma (mouse spleen + myeloma). Bioreactor (serum-free). Protein A/G purification. Concentration 0.5-2mg/mL.
- Polyclonal production: Rabbit immunization (4-6 injections, 2-3 months). Affinity purification (peptide or recombinant column).
- Validation: IHC (human, mouse, rat liver). WB (HepG2, Huh7, primary hepatocytes, 33kDa). IF (membrane staining). ELISA (recombinant ASGR1, LOD 0.1-1ng/mL). Cross-reactivity (ASGR2 knockout tissue, siRNA knockdown). Specificity (no staining in ASGR1-KO mice).
Exclusive Observation – ASGR1 vs. ASGR2: ASGR1 and ASGR2 share 82% homology, requiring careful antibody validation. Monoclonal antibodies (epitope mapping, specific to ASGR1 unique region aa 78-120) have lower cross-reactivity (<5% vs. ASGR2). Polyclonal affinity-purified (peptide-specific) also acceptable. Global leaders (Merck, Thermo Fisher, R&D Systems, Proteintech, Novus, Abcam) dominate validated ASGR1 antibodies (IHC, WB, IF, IP, ELISA), margins 35-45%. Chinese manufacturers (OriGene, Sino Biological, ABclonal, ABnova, Bioss, GeneTex, Affinity Biosciences) have scaled rapidly (35-40% of global volume) with cost advantage 30-50% lower, but lower validation (fewer species, fewer applications). As ASGR1 gains clinical acceptance (NASH diagnostic, HCC prognostic, targeted drug delivery), demand for IVD-grade antibodies (CLIA, CE-IVD) and recombinant antibodies (animal-free, high reproducibility, 10-12% CAGR) will grow.
4. Competitive Landscape and Market Share Dynamics
Key players: Merck (Sigma-Aldrich) (15% share), Thermo Fisher Scientific (12%), R&D Systems (10%), Proteintech Group (9%), Abcam (not listed but notable), Novus Biologicals (7%), OriGene Technologies (5%), others (42% – Aviva Systems Biology, ProSci, RayBiotech, Leading Biology, LifeSpan, EpiGentek, Abbexa, ABclonal, Abnova, BosterBio, Sino Biological, Bioss, United States Biological, GeneTex, Miltenyi Biotec, Affinity Biosciences).
Segment by Antibody Type: Polyclonal (55% market share), Monoclonal (45%, fastest-growing 8% CAGR for ELISA/IF/IP).
Segment by Application: Immunohistochemistry (IHC) (35%), Western Blot (WB) (25%), Immunofluorescence (IF) (15%), ELISA (15%), Immunoprecipitation (IP) (5%), Others (5% – flow cytometry, neutralization).
5. Strategic Forecast 2026-2032
We project the global ASGR1 antibody market will reach 60millionby2032(6.760millionby2032(6.7290-330. Key drivers:
- Liver disease research (NASH, cirrhosis, HCC): NASH 50M patients, cirrhosis 1.5M, HCC 1M. ASGR1 biomarker for hepatocyte differentiation, fibrosis progression, tumor suppression.
- Targeted drug delivery (ASGR1-mediated): Liver-specific siRNA (Mina Therapeutics, Arrowhead), ASO (Ionis), GalNAc-conjugated drugs (Alnylam’s Givlaari, Oxlumo). ASGR1 antibody for receptor visualization, uptake studies, biodistribution.
- Liver regeneration (ASGR1 role): Hepatocyte proliferation, liver repopulation, cell therapy. ASGR1 as marker for mature hepatocytes (vs. fetal, progenitor, iPS-derived hepatocytes).
- Clinical diagnostics (NASH, HCC): Serum soluble ASGR1 (ELISA) as NASH diagnostic (FibroScan), HCC prognostic (tumor grade, survival). CLIA/CE-IVD kits 8-10% CAGR.
Risks include cross-reactivity with ASGR2 (82% homology), batch-to-batch variability (polyclonal 15-25%), and alternative technologies (RNA-seq, MS, CRISPR, spatial transcriptomics). Manufacturers investing in recombinant antibodies (animal-free, high reproducibility, 10-12% CAGR), IVD-grade (CLIA, CE-IVD), and multiplex assays (ASGR1 + albumin, ASGR2, cytokeratin 18, AFP, GP73) will capture share through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
